Dr. Bharti Shetye, also known as Dr. Abby, CEO and Physician Owner of Dr. Abby’s Weight Management Clinic, recently joined Gayle Guyardo, host of the global health and ...

As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

Palatin (PTN) announced positive appetite suppression results from its BMT-801 Phase 2 obesity study. The study included a co-administered ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

It's probably safe to say that weight-loss drugs aren't going anywhere any time soon. According to the most recent data, six percent of American adults, or roughly 16 million people, take such ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

While it is understood that the drugs have also proven to be safe and effective for thousands, the negative issues have led ...

Mounjaro (Terzepatide) is a dual GLP-1/GIP (Gastric Inhibitory Peptide) receptor agonist, which may offer better blood sugar control and enhanced weight loss compared to traditional GLP-1 agonists.

Advances in drug design, such as dual and triple agonists (e.g., GLP-1/gastric inhibitory peptide (GIP) and GLP-1/GIP/glucagon receptor agonists), are expanding the therapeutic impact of these ...

Conducted in partnership with Morning Consult, the study found that GLP-1 users are increasingly prioritizing high-protein, low-carb, and portion-controlled frozen foods, creating new opportunities ...

The data also showed that low dose MC4R agonist bremelanotide stopped the rapid weight regain seen after ending GLP-1/GIP tirzepatide ... MC4R long-acting peptide and oral small molecule compounds ...